Sermorelin Acetate Injection (Lyo) (Each)

Sermorelin Acetate Injection ek synthetic peptide hai jo growth hormone release ko stimulate karne ke liye use hota hai. Yeh injection body ko apne natural growth hormone ko release karne mein madad karta hai, jisse energy, muscle strength, recovery, aur overall wellness mein sudhar hota hai. Isse regular medical supervision mein diya jata hai.

Sermorelin Acetate pituitary gland ko stimulate karta hai, jo growth hormone production ke liye zimmedar hoti hai. Jab ise injection ke roop mein diya jata hai, to yeh hypothalamus se signal jaise kaam karta hai aur pituitary gland ko growth hormone chhodne ke liye utsahit karta hai. Yeh hormone metabolism ko sudharne, fat breakdown ko badhane, aur muscles ko majboot banane mein madad karta hai. Is prakriya se sharir apni prakritik healing aur recovery ko behtar tareeke se support karta hai.

Sermorelin Acetate Injection har kisi ke liye upyukt nahi hai. Agar aapko cancer, thyroid ya adrenal gland se judi samasyaen hain, ya aap kisi gambhir infection se guzar rahe hain to iska upyog doctor ki salah ke bina nahi karna chahiye. Iska use un logon mein bhi saavdhani se kiya jata hai jo diabetes ya hormonal imbalance se peedit hain. Injection shuru karne se pehle apni medical history aur chal rahi medicines ke baare mein apne doctor ko zarur batayen.

Zyada tar log ise achhi tarah tolerate kar lete hain, lekin kuch logon mein halka side effect ho sakta hai. Injection wali jagah par dard, sujan ya redness aam hai. Sir dard, thakan, muh sukhna, ya halki ghabrahat bhi dekhne ko mil sakti hai. Rare cases mein muscle pain, nausea, ya mood swings bhi ho sakte hain. Agar kisi ko allergic reaction, tez dard, ya asamanya lakshan mehsoos ho to turant apne doctor se sampark karna chahiye.

Sermorelin Acetate Injection ka use pregnancy ya breastfeeding ke dauran karne ke baare mein paryapt research uplabdh nahi hai. Isliye bina doctor ki salah ke is dawai ka upyog nahi karna chahiye. Agar kisi mahila ko hormonal imbalance ya anya medical condition ke chalte iska upyog karna ho to medical supervision zaruri hai taki maa aur shishu dono ki suraksha bani rahe.

Store dry powder at 68°F to 77°F (20°C to 25°C) and away from heat, moisture and light. Once reconstituted keep this medicine in a refrigerator between 36°F to 46°F (2°C to 8°C). Keep all medicine out of the reach of children. Throw away any unused medicine after the beyonbeyond-use. Do not flush unused medications or pour down a sink or drain.

1. Wehrenberg WB, Ling N. 1983. “In vivo biological potency of rat and human growth hormone-releasing factor and fragments of human growth hormone-releasing factor”. Biochem Biophys Res Commun. 115 (2): 525–530.
2. Chen, R.G., et al., 1993. A comparative study of growth hormone (GH) and GH-releasing hormone (1-29)-NH2 for stimulation of growth in children with GH deficiency. Acta Paediatr Suppl, 388: p. 32-5; discussion 36.
3. Perez-Romero, A., et al., 1999. Effect of long-term GHRH and somatostatin administration on GH release and body weight in prepubertal female rats. J Physiol Biochem, 55(4): p. 315-24.
4. Tannenbaum, G.S. and Ling N. 1984. The interrelationship of growth hormone (GH)-releasing factor and somatostatin in generation of the ultradian rhythm of GH secretion. Endocrinology, 115(5): p. 1952-7.
5. Tauber, M.T., et al., 1993. Growth hormone (GH) profiles in response to continuous subcutaneous infusion of GH-releasing hormone(1-29)-NH2 in children with GH deficiency. Acta Paediatr Suppl, 388: p. 28-30; discussion 31.
6. Howard AD, Feighner SD, Cully DF et al. 1996, A Receptor in Pituitary and Hypothalamus That Functions in GH release. Science. Vol. 273, Issue 5277, pp. 974-977
7. Esposito, P., et al., 2003. PEGylation of growth hormone-releasing hormone (GRF) analogues. Adv Drug Deliv Rev, 55(10): p. 1279-91.
8. Kirk JM, Trainer PJ, Majrowski WH, Murphy J, Savage MO, Besser GM. 1994. Treatment with GHRH(1-29)NH2 in children with idiopathic short stature induces a sustained increase in growth velocity. Clin Endocrinol (Oxf). 41(4):487-93.
9. Aitman, T.J., et al., 1989. Bioactivity of growth hormone releasing hormone (1-29) analogues after SC injection in man. Peptides, 10(1): p. 1-4.
10. Steiger, A., et al., 1994. Growth hormone-releasing hormone (GHRH)-induced effects on sleep EEG and nocturnal secretion of growth hormone, cortisol and ACTH in patients with major depression. J Psychiatr Res, 28(3): p. 225-38.
11. Mayo, K.E., et al., 1995. Growth hormone-releasing hormone: synthesis and signaling. Recent Prog Horm Res, 50: p. 35-73.
12. Ceda, G.P., et al. 1987. The growth hormone (GH)-releasing hormone (GHRH)-GH-somatomedin axis: evidence for rapid inhibition of GHRH-elicited GH release by insulin-like growth factors I and II. Endocrinology, 120(4): p. 1658-62.
13. Mayo, K.E., et al., Growth hormone-releasing hormone: synthesis and signaling. Recent Prog Horm Res, 1995. 50: p. 35-73.
14. Ceda, G.P., et al., The growth hormone (GH)-releasing hormone (GHRH)-GH-somatomedin axis: evidence for rapid inhibition of GHRH-elicited GH release by insulin-like growth factors I and II. Endocrinology, 1987. 120(4): p. 1658-62.
15. Tannenbaum, G.S. and N. Ling, The interrelationship of growth hormone (GH)-releasing factor and somatostatin in generation of the ultradian rhythm of GH secretion. Endocrinology, 1984. 115(5): p. 1952-7.